Lateral Flow Assays Market Report 2025

The lateral flow assays market size has grown strongly in recent years. It will grow from $11.69 billion in 2024 to $12.39 billion in 2025 at a compound annual growth rate (CAGR) of 6%. The growth in the historic period can be attributed to diagnostic advancements, rise in infectious diseases, application in pregnancy testing, growth in home healthcare, development of immunochromatography, point-of-care testing expansion.

The lateral flow assays market size is expected to see strong growth in the next few years. It will grow to $17.88 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to expanding applications in disease detection, adoption in home testing kits, expansion in veterinary diagnostics, development of multiplex assays, rise in food and environmental testing. Major trends in the forecast period include personalized medicine and home testing, advancements in manufacturing techniques, environmental and food safety testing, focus on cost-effectiveness, application in drug and biomarker detection.

The widespread occurrence of infectious diseases worldwide significantly drives the growth of the lateral flow assay market. In developing nations, the high incidence of infectious diseases such as HIV and malaria, coupled with inadequate healthcare systems and increasing public awareness, is expected to boost the adoption of lateral flow assay testing. The recent COVID-19 pandemic has underscored the necessity for early detection of illnesses, likely propelling market growth. For example, in August 2024, data published by the UK Health Security Agency, a UK-based executive agency, indicated that England reported 368 measles cases in 2023, nearly a sevenfold rise from the 53 cases recorded in 2022, with the West Midlands and London accounting for 44% and 33% of the cases, respectively. Consequently, the high prevalence of infectious diseases globally will contribute to the expansion of the lateral flow assay market.

The increasing prevalence of chronic diseases is poised to drive the growth of the lateral flow assay market in the foreseeable future. Chronic diseases are long-term health conditions that persist over an extended period, often necessitating ongoing medical management. Lateral flow assay is utilized in chronic diseases for rapid and convenient diagnostics, enabling swift on-site testing and monitoring. As of September 2022, according to the World Health Organization, a specialized agency of the United Nations based in Switzerland, approximately 41 million deaths globally each year are attributed to non-communicable diseases (NCDs) or chronic diseases, accounting for 74% of all recorded deaths. These include 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2 million deaths from diabetes. Thus, the escalating prevalence of chronic diseases serves as a driving force for the lateral flow assay market.

Technological advancements are significant trends gaining traction in the lateral flow assays market. Major players in the lateral flow assay market are concentrating on developing innovative testing products to enhance their market position. For example, in February 2022, Abacus Diagnostica, a Finland-based medical device manufacturer, introduced the second generation of COVID-19 testing, the GenomEra SARS-CoV-2 2 Assay Kit. This assay is engineered for the rapid qualitative detection of SARS-CoV-2 in respiratory specimens using a multiplex reverse transcriptase polymerase chain reaction (RT-PCR) method.

Leading companies in the lateral flow assay market are focusing on creating versatile products, such as lateral flow readers, to enable on-the-go testing and gain a competitive advantage. A lateral flow reader is a portable device designed for the quick and qualitative analysis of lateral flow assays, delivering efficient results across various testing environments. For instance, in February 2024, Upfront Diagnostics, a UK-based healthcare firm, launched the Lateral Flow Test for Triaging Stroke Patients. This test, named LVOne, is specifically designed to enhance the speed and accuracy of stroke diagnosis in pre-hospital settings. The LVOne test is a rapid blood test that enables paramedics to identify strokes caused by large vessel occlusions (LVO) within 15 minutes. This prompt identification is critical for fast-tracking patients to specialized stroke centers, where timely treatment can significantly improve outcomes and reduce long-term disabilities.

In December 2023, the U.S.-based software company Danaher Corporation successfully acquired Abcam plc for an undisclosed sum. This strategic move was intended to fortify Danaher Corporation's portfolio and market standing, bolstering its position in the life sciences and diagnostics sector. Abcam PLC, headquartered in the UK, is recognized for producing, distributing, and selling protein research tools along with universal lateral flow assay kits.

Major companies operating in the lateral flow assays market include Siemens AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Hologic Inc., BioMérieux SA, PerkinElmer Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Roche Holding AG, QIAGEN N.V., OraSure Technologies Inc., Meridian Bioscience Inc., DiaSorin S.p.A., Molbio Diagnostics, Trinity Biotech, Chembio Diagnostics Inc., Coris BioConcept, HYCOR Biomedical, Diagnostic BioSystems GmbH, Express Diagnostics Ltd., Fujirebio Diagnostics Inc., Innova Diagnostics Inc., Leadtec Diagnostics Inc., S&D Diagnostics Inc., Standard Diagnostics Inc., V-Chek Diagnostics.

North America was the largest region in the lateral flow assays market in 2024. Asia-Pacific is expected to be the fastest-growing region in the lateral flow assays market share during the forecast period. The regions covered in the lateral flow assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lateral flow assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A lateral flow assay (LFA) consists of four components: a sample pad where the sample is applied, a conjugate pad that combines labeled tags with biorecognition elements, a reaction membrane featuring test and control lines for the interaction between the target antigen and antibody, and an absorbent pad that collects waste.

The primary categories of lateral flow assays include kits and reagents, along with lateral flow readers. Lateral flow readers are instruments designed for reading and analyzing the results obtained from lateral flow tests. Lateral flow assays operate based on techniques such as sandwich assays, competitive assays, and multiplex detection assays. These assays find applications in various fields, including veterinary diagnostics, clinical/point-of-care testing, drug development and quality testing. They are utilized by hospitals and clinics, diagnostic laboratories, home care settings, as well as pharmaceutical and biotechnology companies, among other end users.

The lateral flow assays market research report is one of a series of new reports that provides lateral flow assays market statistics, including lateral flow assays industry global market size, regional shares, competitors with a lateral flow assays market share, detailed lateral flow assays market segments, market trends, and opportunities, and any further data you may need to thrive in the lateral flow assays industry. This lateral flow assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The lateral flow assay market consists of the sale of kits, reagents, and assemblies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this lateral flow assay market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.